NEW YORK (GenomeWeb News) – Prometheus Laboratories has licensed US rights to Rosetta Genomics' recently introduced microRNA-based tests and has taken an equity stake in the molecular diagnostics firm.

San Diego-based Prometheus has gained the right to sell the miRview mets, miRview squamous, and miRview meso, which Rosetta launched in late 2008. It will provide Rosetta with payments, either in the form of milestones or R&D funding, and royalties based on net sales in the US.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

CNN reports that researchers have tied a new variant to opioid addiction risk.

Organoids derived from patients' tumors may help determine what chemotherapy treatment patients would benefit from, according to New Scientist.

An initiative from GenomeAsia 100K hopes to increase the number of South Asians in genetic research, according to NBC News.

In Science this week: genomic analysis of ancient and modern horses indicates population turnover, and more.

Mar
08
Sponsored by
Swift Biosciences

This webinar will discuss an optimized protocol for methyl-CpG binding domain sequencing (MBD-seq), which enables comprehensive, adequately powered, and cost-effective large-scale methylome-wide association studies (MWAS) of almost all 28 million CpG sites in the genome.

Mar
13
Sponsored by
Agilent

This webinar will share how clinical genetics labs can integrate cytogenetics and molecular data to assess abnormalities using a single sample on a single workflow platform.

Apr
03
Sponsored by
Dovetail Genomics

Proximity ligation technology generates multi-dimensional next-generation sequencing data that is proving to solve unmet needs in genomic research.